Research On The Effect Of R ＆ D Cost Plus Deduction Policy On The Performance Of Lepu Medical

In 2018,Sino-US trade frictions posed a severe challenge to China’s technological innovation capacity.Facing the complex and changeable international situation,we must improve scientific and technological innovation capacity,so as to have a place in the rapidly developing international market.In the face of such a severe international environment,in order to encourage enterprises to continue technological innovation,the government has expanded the scope of application of the 75% deduction rate of R＆D expense from medium-sized enterprises to the whole enterprise.Then for Chinese medical device enterprises,how will the huge change of this policy affect them?Based on the theoretical bases of endogenous growth,cost management,market failure and tax incentive,this paper takes Lepu medical as the research object.Firstly,the current research literature of domestic and foreign scholars is sorted out,which can be roughly divided into three sections: R＆D expense additional deduction policy and R＆D investment,R＆D expense additional deduction policy and enterprise performance,R＆D investment and enterprise performance.Then it introduces the measurement index of R＆D investment and performance,which lays a foundation for the case introduction and case analysis in the following paper.Finally,starting case introduction and case analysis.The first step is to summarize the R＆D investment and performance of the medical industry.The second step is to select the data of Lepu medical from 2015 to 2020,and take R＆D investment as a link between the Policy and corporate performance,and make a analysis of the impact of policy changes on enterprise funds and R ＆ D personnel.The third step is to explore the impact of R＆D investment on financial performance and innovation performance.Financial performance is analyzed from the four major capabilities and EVA,while innovation performance is analyzed from the medical device registration certificate and the increase in internal R＆D of intangible assets.Finally,the conclusion is drawn: "the policy change of R ＆ D expense plus deduction has mobilized the enthusiasm of R ＆ D investment and promoted enterprise performance,but the R ＆ D investment of Lepu medical still needs to be improved,the definition of R ＆ D investment capitalization in accounting policy is unclear,and the output of innovation achievements of enterprises still lags behind the leading enterprises".Therefore,in order to more effectively promote enterprises to actively carry out technological innovation and realize the sustainable development of the company,this paper puts forward the following suggestions: deeply implement and increase the innovation investment in enterprises;Refine the capitalization standard of R ＆ D expenditure of medical device enterprises;Strengthen and encourage the transformation rate of R ＆ D achievements of enterprises.